PROCEPT BioRobotics (US:PRCT)2024-10-28 11:28BPH Market and Unmet Needs - Benign Prostatic Hyperplasia (BPH) affects approximately 40 million men in the U S [10] - Approximately 6 7 million U S men are actively managed for BPH [11] - The U S BPH surgical market represents a $20B+ opportunity [8, 16] - Up to 30% of patients discontinue BPH medications within 2 years due to minimal symptom impact and side effects [18] - Resective surgeries, while effective, have limitations in safety, with complications like ejaculatory dysfunction occurring in as high as 89% of cases [22] Aquablation Therapy and HYDROS Robotic System - The HYDROS Robotic System is a next-generation system for Aquablation therapy, featuring AI-powered treatment planning and advanced image guidance [24] - Aquablation therapy has demonstrated similar efficacy to TURP across all prostate sizes in clinical and commercial studies [36] - Clinical data shows low rates of irreversible complications with Aquablation in all prostates, including 0 0% incontinence and 0 0% erectile dysfunction in WATER and WATER II studies [37] - Approximately 70% of prostates treated with Aquablation in the U S are <100 mL [47] Financial Performance and Guidance - Worldwide revenue for the company reached $58 4 million in 3Q24, a 66% year-over-year increase [73] - U S systems sold increased by 18% year-over-year, with 445 systems installed [73] - The company projects total revenue between $222 5 million and $223 0 million for FY24, representing a 63% to 64% year-over-year growth [78, 81]